5-Amino-1MQ

No study cited here has given 5-Amino-1MQ to a human being, so there is no human data on it at all. What exists is a short stack of mouse and cell culture work from one academic group, built on an enzyme target that other labs have studied independently.

The reason it gets attention is a single result. In 2018, male mice made obese on a high-fat diet were treated with it for 11 days. They lost about 5 percent of their body weight while untreated mice gained a little, their main abdominal fat pad shrank by roughly 35 percent, and they ate about the same amount of food as the controls. A second mouse study from the same group, in 24-month-old animals, found injured leg muscle regrew larger fibers and produced more force.

It is also not a peptide, despite being sold beside them. It is a small synthetic molecule that blocks an enzyme called NNMT. Everything known about what it does comes from mice and cultured cells.

5-Amino-1MQ is short for 5-amino-1-methylquinolinium. Chemically it is a methylquinolinium ring with an amine group added at one position. The research group at the University of Texas Medical Branch that characterised it was screening a series of these quinolinium compounds for one property in particular: whether they could get through cell membranes, because the enzyme they target sits inside the cell.

The amine substitution is what made the difference. Earlier members of the series barely crossed membranes, while 5-Amino-1MQ moved across both by passive diffusion and by active transport in standard lab permeability assays, with no detectable pumping back out. That property, more than raw potency, is why it became the compound the group took into mice.

A peptide is a chain of amino acids. 5-Amino-1MQ has none. Grouping it with peptides is a catalogue habit, not chemistry.

The Enzyme It Blocks

NNMT, nicotinamide N-methyltransferase, attaches a methyl group to nicotinamide, a form of vitamin B3 that cells use to build NAD+. The methyl group comes from SAM, the cell's general methyl donor. Each reaction therefore uses up one molecule of an NAD+ precursor and one molecule of SAM, and leaves behind a product called 1-methylnicotinamide.

That places NNMT at a junction between energy metabolism and the methylation chemistry cells use to regulate genes. In obese and diabetic mice, NNMT expression is higher in white fat and liver. In people, fat tissue NNMT expression is higher with insulin resistance and type 2 diabetes. Those human observations measure the body's own enzyme; they say nothing about the drug.

What the Inhibitor Did in Cells

In cultured mouse fat cells, 5-Amino-1MQ lowered the enzyme's product, raised NAD+ about 1.2 to 1.6 fold across the concentrations tested, raised SAM at the higher concentrations, and cut new fat accumulation by 50 to 70 percent in cells being pushed to become fat cells. It did not meaningfully inhibit the related methyltransferases or the NAD+ recycling enzymes it was tested against, so the effect looks specific to NNMT.

The Complication

NNMT is not simply a bad actor. Reviewers of the field note that in the liver its activity is associated with better lipid profiles, while in fat tissue higher levels track with obesity and insulin resistance. Blocking it everywhere at once is not the same as turning down only the fat-tissue version.

Citing the 2014 Nature paper as proof the compound works. That study lowered NNMT with antisense oligonucleotides. It never used 5-Amino-1MQ. It is the reason the target is interesting, not evidence about this molecule.

Treating 11 days in mice as a fat-loss result. The obesity data are one experiment, 18 male mice, one diet, eleven days. A 5 percent weight change over that window says the compound does something to mouse metabolism. It says nothing about duration, rebound, females, or people.

Turning the muscle study into a strength claim. The aged mice were recovering from a chemical injury, and their force gain disappeared once fiber size was accounted for. That is a regeneration finding in injured old mice, not evidence of strength gains in healthy muscle.

Assuming genetic results transfer cleanly to the drug. When the gene was removed entirely, effects depended on sex and diet, and glucose tolerance did not improve. An inhibitor that partly blocks the enzyme for some hours a day is a different intervention again, and the only data on it are the two studies above.

Human safety is unknown, because no person has been studied. The animal record is thin: the 2018 authors reported no observable adverse effects in 9 treated mice over 11 days and in a 2-mouse pilot run before the main study. In cultured fat precursor cells the compound began to show modest toxicity at higher concentrations and killed about 40 percent of cells at the highest concentration tested. Long-term exposure, effects on the liver, where NNMT appears to play a protective role in lipid handling, and effects in females have not been examined for this compound.

What the record shows: a membrane-permeable, NNMT-selective inhibitor that shrank fat in obese male mice over 11 days without changing how much they ate, and helped injured muscle in old male mice regrow larger fibers. The underlying target has independent support from genetic studies in mice.

What it does not show: anything at all about people, anything beyond a few weeks in animals, or anything from a lab outside the group that developed it. The genetic work adds a caution that NNMT effects depend on sex, diet and tissue.

The thing to watch for is a first human study. Until one is published, 5-Amino-1MQ is a mouse result with a sensible mechanism behind it.

Not a peptide. It is a small methylquinolinium molecule with no amino acid chain. Its ability to cross cell membranes, which most peptides lack, is the reason it was chosen for testing.

Not an approved medicine, and not sorted by FDA for compounding either way. It is not FDA approved. It does not appear on FDA's Category 1 or Category 2 lists for bulk compounding substances, and FDA has said it does not intend to categorise substances nominated on or after 7 January 2025, so that absence says nothing about safety or legality.

Not the compound in the Nature paper. The 2014 study that made NNMT a fat-loss target used antisense knockdown. Any page presenting it as evidence for 5-Amino-1MQ has not read the methods.

Not permitted in tested sport. It is not named on the WADA Prohibited List, but S0 prohibits at all times any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use. 5-Amino-1MQ has no such approval, so S0 captures it. No WADA or national anti-doping ruling names it, and absence from the list is not permission.

I keep 5-Amino-1MQ in the library because it is a clean example of a real target with almost nothing built on top of it yet. NNMT is a legitimate piece of metabolic biology, and the mouse result is tidy: fat down, food intake unchanged, over a short window.

What I cannot get past is how small the foundation is. Two mouse studies, all male animals, one research group, and the longest treatment measured in weeks. The genetic studies that are supposed to back it up turned out to depend on sex and diet. That is not a reason to dismiss it. It is a reason to wait for someone outside the original lab to reproduce the result, and for anyone at all to run a first study in people.

If that study appears, I will rewrite this page around it. Until then I am treating 5-Amino-1MQ as an interesting mouse finding and nothing more.